|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
ES2445208T3
(es)
|
2002-07-29 |
2014-02-28 |
Rigel Pharmaceuticals, Inc. |
Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
|
|
BRPI0413018B8
(pt)
|
2003-07-30 |
2021-05-25 |
Rigel Pharmaceuticals Inc |
composto, e, uso de um composto
|
|
AU2011253635B2
(en)
*
|
2003-09-17 |
2014-10-30 |
Janssen Pharmaceutica, N.V. |
Fused heterocyclic compounds
|
|
SI1668014T1
(sl)
|
2003-09-17 |
2009-06-30 |
Janssen Pharmaceutica Nv |
Kondenzirane heterociklične spojine kot modulatorji serotoninskih receptorjev
|
|
WO2005068473A1
(en)
*
|
2003-12-17 |
2005-07-28 |
Sgx Pharmaceuticals, Inc. |
Bicyclic pyrazolo-fused compounds as protein kinase modulators
|
|
WO2005123111A2
(en)
*
|
2004-06-21 |
2005-12-29 |
Exelixis, Inc. |
Maxs as modifiers of the axin pathway and methods of use
|
|
US7820654B2
(en)
|
2004-09-23 |
2010-10-26 |
Dr. Reddy's Laboratories Ltd. |
Pyrimidine compounds, process for their preparation and compositions containing them
|
|
DE602006010979D1
(de)
|
2005-01-19 |
2010-01-21 |
Rigel Pharmaceuticals Inc |
Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
|
|
US20070203161A1
(en)
*
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
WO2006133426A2
(en)
|
2005-06-08 |
2006-12-14 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
CA2642229C
(en)
|
2006-02-24 |
2015-05-12 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
CA2650140A1
(en)
|
2006-04-14 |
2007-10-25 |
Mriganka Sur |
Identifying and modulating molecular pathways that mediate nervous system plasticity
|
|
BRPI0714409A2
(pt)
*
|
2006-07-14 |
2013-03-12 |
Novartis Ag |
derivados de pirimidina como inibidores de alk-5
|
|
JP2010508363A
(ja)
*
|
2006-11-01 |
2010-03-18 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ヤヌスキナーゼの阻害剤として有用な三環系ヘテロアリール化合物
|
|
US20100137398A1
(en)
*
|
2007-05-04 |
2010-06-03 |
Novartis Ag |
Use of hdac inhibitors for the treatment of gastrointestinal cancers
|
|
US8309566B2
(en)
|
2008-02-15 |
2012-11-13 |
Rigel Pharmaceuticals, Inc. |
Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases
|
|
MX2010011463A
(es)
|
2008-04-16 |
2011-06-03 |
Portola Pharm Inc |
2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.
|
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
NZ588830A
(en)
*
|
2008-04-22 |
2012-11-30 |
Portola Pharm Inc |
Inhibitors of protein kinases
|
|
EP2370437B1
(en)
|
2008-11-25 |
2013-09-04 |
Nerviano Medical Sciences S.r.l. |
Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
|
|
CA2752150A1
(en)
*
|
2009-02-11 |
2010-08-19 |
Reaction Biology Corp. |
Selective kinase inhibitors
|
|
US8663210B2
(en)
|
2009-05-13 |
2014-03-04 |
Novian Health, Inc. |
Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
|
|
JO3030B1
(ar)
*
|
2009-06-26 |
2016-09-05 |
Galapagos Nv |
مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
|
|
CA2767089A1
(en)
*
|
2009-07-15 |
2011-01-20 |
Abbott Laboratories |
Pyrrolopyridine inhibitors of kinases
|
|
CN102470135A
(zh)
*
|
2009-07-28 |
2012-05-23 |
里格尔药品股份有限公司 |
抑制jak途径的组合物和方法
|
|
US20120157453A1
(en)
*
|
2009-08-28 |
2012-06-21 |
Genentech, Inc. |
Raf inhibitor compounds and methods of use thereof
|
|
UY33213A
(es)
*
|
2010-02-18 |
2011-09-30 |
Almirall Sa |
Derivados de pirazol como inhibidores de jak
|
|
US9102625B2
(en)
|
2010-11-01 |
2015-08-11 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as JAK kinase modulators
|
|
US9198911B2
(en)
|
2010-11-02 |
2015-12-01 |
The Trustees Of Columbia University In The City Of New York |
Methods for treating hair loss disorders
|
|
CA3094793A1
(en)
|
2011-11-23 |
2013-05-30 |
Portola Pharmaceuticals, Inc. |
Pyrazine kinase inhibitors
|
|
WO2013113762A1
(en)
|
2012-01-31 |
2013-08-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for predicting the risk of having a cutaneous melanoma in a subject
|
|
EP3459565A1
(en)
*
|
2012-03-29 |
2019-03-27 |
The Trustees of Columbia University in the City of New York |
Methods for treating hair loss disorders
|
|
JP6378171B2
(ja)
|
2012-04-24 |
2018-08-22 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
Ｄｎａ−ｐｋ阻害剤
|
|
WO2014013014A1
(en)
|
2012-07-18 |
2014-01-23 |
Fundació Privada Centre De Regulació Genòmica (Crg) |
Jak inhibitors for activation of epidermal stem cell populations
|
|
US9676756B2
(en)
|
2012-10-08 |
2017-06-13 |
Portola Pharmaceuticals, Inc. |
Substituted pyrimidinyl kinase inhibitors
|
|
SI3527563T1
(sl)
|
2013-03-12 |
2022-01-31 |
Vertex Pharmaceuticals Incorporated |
Inhibitorji DNA-PK
|
|
RU2675270C2
(ru)
|
2013-10-17 |
2018-12-18 |
Вертекс Фармасьютикалз Инкорпорейтед |
Сокристаллы и содержащие их фармацевтические композиции
|
|
CN106458990B
(zh)
*
|
2014-04-04 |
2019-06-07 |
希洛斯医药品股份有限公司 |
细胞周期蛋白依赖性激酶7(cdk7)的抑制剂
|
|
RU2742305C2
(ru)
*
|
2014-12-30 |
2021-02-04 |
Новира Терапьютикс, Инк. |
Производные и способы лечения инфекций гепатита в
|
|
CN108472298B
(zh)
|
2015-11-24 |
2021-04-20 |
深圳阿拉丁医疗科技有限公司 |
选择性激酶抑制剂
|
|
WO2018041989A1
(en)
|
2016-09-02 |
2018-03-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating refractory celiac disease type 2
|
|
RU2758669C2
(ru)
|
2016-09-27 |
2021-11-01 |
Вертекс Фармасьютикалз Инкорпорейтед |
Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк
|
|
US10759865B2
(en)
|
2017-08-22 |
2020-09-01 |
Eyal Levit |
Treatment of diabetes mellitus
|
|
WO2019046316A1
(en)
*
|
2017-08-28 |
2019-03-07 |
Acurastem Inc. |
PIKFYVE KINASE INHIBITORS
|
|
CN108586341B
(zh)
*
|
2018-05-25 |
2020-05-08 |
天津商业大学 |
酰胺类化合物和其药用盐及其制备方法和药物用途
|
|
US20220143049A1
(en)
|
2019-03-21 |
2022-05-12 |
Onxeo |
A dbait molecule in combination with kinase inhibitor for the treatment of cancer
|
|
JP2022527972A
(ja)
|
2019-04-02 |
2022-06-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
前悪性病変を有する患者において癌を予測及び予防する方法
|
|
US20220202820A1
(en)
|
2019-04-16 |
2022-06-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
|
|
EP4054579A1
(en)
|
2019-11-08 |
2022-09-14 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
CN114605390B
(zh)
*
|
2020-12-04 |
2024-08-16 |
上海凌达生物医药有限公司 |
具有cdk激酶抑制活性的化合物、其药物组合物和用途
|
|
AU2022271290A1
(en)
|
2021-05-07 |
2023-11-23 |
Kymera Therapeutics, Inc. |
Cdk2 degraders and uses thereof
|
|
EP4526469A1
(en)
|
2022-05-16 |
2025-03-26 |
Institut National de la Santé et de la Recherche Médicale |
Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation
|
|
WO2026024674A1
(en)
|
2024-07-22 |
2026-01-29 |
Genesis Therapeutics, Inc. |
Methods of treating skp2-associated cancers
|